Abstract
Objective
To evaluate the long-term outcome of percutaneous septal ablation (PTSMA) after a previous myectomy.
Background
Myectomy usually results in symptomatic improvement and reduction of dynamic obstruction in hypertrophic obstructive cardiomyopathy patients (HOCM-pts.). However, a few pts. remain with severe symptoms and obstruction, and need additional interventions.
Methods
We reviewed our database of 450 pts. who underwent PTSMA in our institution, and identified 11 (7 women, 4 men, mean age: 50 ± 14 years) with residual or recurrent NYHA class symptoms ≥III and significant left ventricular outflow obstruction (LVOTO) despite a previous myectomy 4 ± 5 years ago. In-hospital and follow-up data covering 6 ± 4 years, focusing on mortality and morbidity, symptoms, exercise capacity, and echocardiographic measures were collected.
Results
PTSMA was performed by injection of 3.6 ± 2.9 ml of alcohol. There was no peri-procedural or late death in this cohort. CK peaked at 614 ± 434 U/l. In addition to two pts. who already had a pacemaker implanted, two more (18%) who both had pre-existing left bundle branch block were pacemaker-dependent after PTSMA. During follow-up, 9 pts. (81%) reported significant and stable improvement. Two pts. (18%) developed progressive class III symptoms until their last follow-up, one of these together with persistent AF and a non-fatal stroke, the other received an ICD for primary prophylaxis and entered our pre-transplant program. Echo-Doppler showed sustained LVOTO elimination without global LV dilatation in all cases.
Conclusions
PTSMA is an effective non-surgical option for treating symptoms and residual or recurrent LVOTO after a previous surgical myectomy. The high rate of conduction disturbances in this post-surgical cohort translated into a higher rate of pacemaker dependency after PTSMA.
Similar content being viewed by others
References
Faber L, Meissner A, Ziemssen P, Seggewiss H (2000) Percutaneous transluminal septal myocardial ablation for HOCM: long-term follow-up in the first series of 25 patients. Heart 83:326–331
Faber L, Seggewiss H, Gietzen FH, Kuhn H, Boekstegers P, Neuhaus L, Seipel L, Horstkotte D (2005) Follow-up results of the “TASH”-registry of the German Cardiac Society. Z Kardiol 94:516–523
Faber L, Seggewiss H, Gleichmann U (1998) Percutaneous transluminal septal myocardial ablation in hypertrophic obstructive cardiomyopathy: Results with respect to intra-procedural myocardial contrast echocardiography. Circulation 98:2415–2421
Faber L, Seggewiss H, Ziemssen P (2000) Targeting percutaneous transluminal septal ablation for HOCM by intra-procedural echocardiographic monitoring. J Am Soc Echocardiogr 13:1074–1079
Faber L, Welge D, Fassbender D, Schmidt HK, Horstkotte D, Seggewiss H (2007) Percutaneous septal ablation for symptomatic hypertrophic obstructive cardiomopathy: managing the risk of procedure-related AV conduction. Disturbances. Int J Cardiol 119:163–167
Fernandes VL, Nagueh SF, Wang R, Roberts R, Spencer WH (2005) A prospective follow-up of alcohol septal ablation for symptomatic hypertrophic obstructive cardiomyopathy: the Baylor experience (1996–2002). Clin Cardiol 28:124–130
Joyal D, Arab D, Chen-Johnston C, Leya F (2007) Alcohol septal ablation after failed surgical myectomy. Catheter Cardiovasc Interv 69:999–1002
Kuhn H, Gietzen F, Leuner C, Gerenkamp T (1997) Induction of subaortic septal ischemia to reduce obstruction in hypertrophic obstructive cardiomyopathy. Eur Heart J 18:846–851
Lakkis NM, Nagueh SF; Kleiman NS, Killip DM, He ZX, Verani M, Roberts R, Spencer WH III (1998) Echocardiography-guided ethanol septal reduction for hypertrophic obstructive cardiomyopathy. Circulation 98:1750–1755
Maron BJ, McKenna WJ, Danielson GK, Kappenberger LJ, Kuhn HJ, Seidman CE, Shah PM, Spencer WH 3rd, Spirito P, Ten Cate FJ, Wigle ED, Vogel RA, Abrams J, Bates ER, Brodie BR, Danias PG, Gregoratos G, Hlatky MA, Hochman JS, Kaul S, Lichtenberg RC, Lindner JR, O’Rourke RA, Pohost GM, Schofield RS, Tracy CM, Winters WL Jr, Klein WW, Priori SG, Alonso-Garcia A, Blomstrom-Lundqvist C, De Backer G, Deckers J, Flather M, Hradec J, Oto A, Parkhomenko A, Silber S, Torbicki A. American College of Cardiology/European Society of Cardiology clinical expert consensus document on hypertrophic cardiomyopathy (2003) A report of the American College of Cardiology foundation task force on clinical expert consensus documents and the European Society of Cardiology Committee for practice guidelines. J Am Coll Cardiol 42:1687–713
Minakata K, Dearani JA, Schaff HV, O’Leary PW, Ommen SR, Danielson GK (2005) Mechanisms for recurrent left ventricular outflow tract obstruction after septal myectomy for obstructive hypertrophic cardiomyopathy. Ann Thorac Surg 80:851–856
Minami K, Boethig D, Woltersdorf H, Seifert D, Koerfer R (2002) Long term follow-up of surgical treatment of hypertrophic obstructive cardiomyopathy (HOCM): the role of concomitant cardiac procedures. Eur J Cardiothorac Surg 22:206–210
Nagueh SF, Buergler JM, Quinones MA, Spencer WH III, Lawrie GM (2007) Outcome of surgical myectomy after unsuccessful alcohol septal ablation for the treatment of patients with hypertrophic obstructive cardiomyopathy. J Am Coll Cardiol 50:795–798
Ommen SR, Maron BJ, Olivotto I, Maron MS, Cecchi F, Betocchi S, Gersh BJ, Ackerman MJ, McCully RB, Dearani JA, Schaff HV, Danielson GK, Tajik AJ, Nishimura RA (2005) Long-term effects of surgical septal myectomy on survival in patients with obstructive hypertrophic cardiomyopathy. J Am Coll Cardiol 46:470–476
Robbins RC, Stinson EB, Daily PO (1996) Long-term results of left ventricular myotomy and myectomy for obstructive hypertrophic cardiomyopathy. J Thorac Cardiovasc Surg 111:586–594
Schulte HD, Bircks W, Lösse B (1987) Techniques and complications of transaortic subvalvular myectomy in patients with hypertrophic obstructive cardiomyopathy (HOCM). Z Kardiol 76(Suppl 3):145–151
Seggewiss H, Gleichmann U, Faber L, Fassbender D, Schmidt HK, Strick S (1998) Percutaneous transluminal septal myocardial ablation in hypertrophic obstructive cardiomyopathy: acute results and 3-months follow-up in 25 patients. J Am Coll Cardiol 31:252–258
Sigwart U (1995) Non-surgical myocardial reduction for hypertrophic obstructive cardiomyopathy. Lancet 346:211–214
Talreja DR, Nishimura RA, Edwards WD, Valeti US, Ommen SR, Tajik AJ, Dearani JA, Schaff HV, Holmes DR Jr (2004) Alcohol septal ablation versus surgical septal myectomy: comparison of effects on atrioventricular conduction tissue. J Am Coll Cardiol 44:2329–2332
Valettas N, Rho R, Beshai J, Lloyd CT, Ross HM, Kocovic D, Herrmann HC (2003) Alcohol septal ablation complicated by complete heart block and permanent pacemaker failure. Catheter Cardiovasc Interv 58:189–193
Woo A, Williams WG, Choi R, Wigle ED, Rozenblyum E, Fedwick K, Siu S, Ralph-Edwards A, Rakowski H (2005) Clinical and echocardiographic determinants of long-term survival after surgical myectomy in obstructive hypertrophic cardiomyopathy. Circulation 111:2033–2041
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Faber, L., Welge, D., Hering, D. et al. Percutaneous septal ablation after unsuccessful surgical myectomy for patients with hypertrophic obstructive cardiomyopathy. Clin Res Cardiol 97, 899–904 (2008). https://doi.org/10.1007/s00392-008-0707-0
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00392-008-0707-0